Brade DeBriere retweeted
The time for health equity is now. Actor and Artist Ice-T @FINALLEVEL is helping the IMF raise awareness of multiple myeloma in the Black Community this #BlackHistoryMonth Watch Now: youtu.be/UpZCpVMMphQ #IMFMPOWER
@jmikhaelmd
Brade DeBriere retweeted
This #BlackHistoryMonth, we are highlighting disparities in #myeloma care. Black Americans are twice as likely to develop myeloma but face barriers to care. Learn more & join the fight for equity: mmsm.link/4ahUTUK
@jmikhaelmd
Brade DeBriere retweeted
On Sept 18 don't miss our webinar on the timely diagnosis of myeloma in diverse populations! Learn about healthcare disparities and testing methods. Register here: buff.ly/3Z6gGev
Brade DeBriere retweeted
Mark your calendar to join this #webinar on September 18 at 12:00pm EDT! Click to Register!
➡️eu1.hubs.ly/H0bWPsT0
#sebia #sebiausa #myeloma #Freelightchain #FLC #diagnosis #patientcare
Brade DeBriere retweeted
CONGRESS | #COMy2024 | @IrenemGhobrial @DanaFarber shares the strategies for smoldering myeloma risk stratification. Ghobrial discusses the challenges in defining HR-SMM, suggesting methods to further refine risk criteria, and emphasising the benefits of early intervention in SMM.
#mmsm #myeloma #multiplemyeloma @COMyCongress
During my UTSW laboratory rotation, out of 100 people we surveyed on the hospital campus, only 3 knew what a Medical Technologist (MLS) was and only 1 understood what we do! I love the ending of this video...it says it all.
Every day and all through the night, #MedLab professionals work tirelessly #BehindEveryPatient.
We perform millions of tests every year, analyzing samples to inform diagnosis and keep you and your loved ones safe.
Brade DeBriere retweeted
I started the EVIDENCE meta-analysis in 2009. After 15 yrs of work, I will present 4/12 at ODAC: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patients’ access to new drugs?
#mmsm @theMMRF @IMFmyeloma youtube.com/live/pooME9gMaL0…
Brade DeBriere retweeted
Huge win for #myeloma patients today! The ODAC committee approved MRD testing as an early endpoint for MM drugs in trials. This accelerates progress towards new treatments! Thank you all who participated @NikhilMunshiMD @DrOlaLandgren @IMFmyeloma + #mmsm myeloma.org/news-events/mult…
Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains - Read on degruyter.com/document/doi/1… @degruyter_brill
1
2
91
Brade DeBriere retweeted
Visit Sebia at ASH in San Diego, Booth #2455 to hear about M-inSight, our new serum-based MRD test for monitoring Multiple Myeloma.
Schedule time with our team of experts to learn more about this new assay:
bit.ly/3sTjX32
#ASH23 #sebia #minsight #multiplemyeloma
Brade DeBriere retweeted
Dr. Ben Andress showed that Sebia FLC measurement has equivalent value in risk stratification of MGUS patients compared to FreeLite. @ACLPS_ @MayoClinicPath #aclps2023
Brade DeBriere retweeted
Dynamic monitoring of MRD in myeloma with targeted mass spectrometry. #OpenAccess nature.com/articles/s41408-0…
“Simple algebraic equation” to increase specificity of sFLC tests without eGFR based stratification. I might need a refresher course :)
Brade DeBriere retweeted
We tested the Sebia free light chain assay performance in the established cutpoints for MM diagnosis (iFLCr of 100) and high-risk SMM in a cohort of SMM patients. The test performance is equivalent to the comparator/reference test. rdcu.be/cVI7q @BloodCancerJnl – at Minnesota, USA





















